Neoadjuvant Therapy This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest news and research items in this category.

Androgen deprivation for prostate cancer.
Abstract Androgen deprivation therapy (ADT) is the mainstay systemic treatment of prostate cancer because of the androgen dependence of the disease. Although ADT has long been used to manage prostate cancer, its use continues to evolve as data from clinical trials mature and long-term effects are recognized. For patients with localized disease and high-risk features, short and long courses of ADT as neoadjuvant/adjuvant therapy have been shown to improve survival when used with radiation therapy, but this has not been demonstrated with radical prostatectomy. The role of ADT with salvage radiotherapy after radical p...
Source: Clinical Prostate Cancer - June 16, 2013 Category: Cancer & Oncology Authors: Chi KN, Nguyen PL, Higano CS Tags: Am Soc Clin Oncol Educ Book Source Type: research

Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis [Sarcomas]
Conclusion These results suggest fundamental differences in the way chemotherapy is handled by females compared with males and by children compared with older populations. These differences may influence survival in a disease in which chemotherapy is critical to overall outcomes. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 14, 2013 Category: Cancer & Oncology Authors: Collins, Wilhelm, Conyers, Herschtal, Whelan, Bielack, Kager, Kuhne, Sydes, Gelderblom, Ferrari, Picci, Smeland, Eriksson, Petrilli, Bleyer, Thomas Tags: Osteosarcoma, Chemotherapy Sarcomas Source Type: research

PET And MR Predict Chemotherapy's Ability To Prolong Life Of Breast Cancer Patients
For patients with advanced breast cancer, positron emission tomography (PET) and magnetic resonance (MR) imaging can improve quality of life and survival by providing physicians with information on the effectiveness of chemotherapy prior to surgery, said researchers presenting at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging. Researchers combined separate imaging systems - PET, MR and CT - to map the course of chemotherapy before surgery, otherwise known as neoadjuvant chemotherapy... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 13, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Neoadjuvant Chemotherapy for Gastric CancerNeoadjuvant Chemotherapy for Gastric Cancer
How effective is neoadjuvant chemotherapy in the treatment of gastric cancer? This new study examines the latest research. Journal of Gastroenterology and Hepatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 12, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

The Role of Chemotherapy in the Management of Stage IIIA Non-Small Cell Lung Cancer.
Abstract Patients with confirmed stage IIIA non-small cell lung cancer (NSCLC) represent a very heterogeneous group which includes those with limited microscopic ipsilateral mediastinal lymph node involvement discovered after a surgical resection, as well as those who have radiologically evident bulky subcarinal lymph node involvement at presentation. Different therapeutic options in stage IIIA disease include neoadjuvant chemo- or chemoradiotherapy followed by surgery, primary surgery followed by adjuvant chemotherapy with or without sequential adjuvant radiation therapy or definitive chemoradiation without surger...
Source: Clinical Lung Cancer - June 12, 2013 Category: Cancer & Oncology Authors: Baik CS, Vallières E, Martins RG Tags: Am Soc Clin Oncol Educ Book Source Type: research

Long‐term Significance (15 years) of Pathological Complete Response after Dose‐dense Neoadjuvant Chemotherapy in Breast Cancer
(Source: The Breast Journal)
Source: The Breast Journal - June 11, 2013 Category: Cancer & Oncology Authors: Qian Wang‐Lopez, Catherine Abrial, Eloïse Planchat, Marie‐Ange Mouret‐Reynier, Hervé Cure, Pierre Gimbergues, Pascale Dubray‐Longeras, Emilie Gadea, Fabrice Kwiatkowski, Frédérique Penault‐Llorca, Philippe Chollet, Xavier Durando Tags: Letter to the Editor Source Type: research

Sequential preoperative hepatic vein embolization after portal vein embolization for extended left hepatectomy in colorectal liver metastases
Conclusion: Sequential portal vein embolization and hepatic vein embolization for extended left hepatectomy may be considered to increase FLR and may prevent right hepatic congestion after sacrificing the middle vein. (Source: World Journal of Surgical Oncology)
Source: World Journal of Surgical Oncology - June 11, 2013 Category: Cancer & Oncology Authors: Gitonga MuneneRobyn ParkerJohn LarriganJason WongFrancis SutherlandElijah Dixon Source Type: research

Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas -- PRODIGE 19 -- FFCD1103 -- ADCI002
DiscussionAs inherent chemo resistance of signet ring cell tumours and delay in definitive surgery may favour tumour progression we hypothesise that a policy of primary surgery followed by adjuvant chemotherapy will improve overall survival compared to a standard perioperative chemotherapeutic strategy. This randomised phase II/III trial is the first dedicated to this histological subtype. Whilst the development of new biomarkers and targeted therapies are awaited, the results of this trial should further help in devising individualised protocols of patient care in a tumour group whose diversity increasingly demands assess...
Source: BMC Cancer - June 10, 2013 Category: Cancer & Oncology Authors: Guillaume PiessenMathieu MessagerKarine Le MalicotWilliam RobbFrédéric Di FioreMarie GuilbertMarie MoreauVéronique ChristopheAntoine AdenisChristophe Mariette Source Type: research

ASCO: Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy by Subtype
In a study presented at ASCO, a team of researchers used microarrays to characterize 130 triple-negative breast cancer patients treated with neoadjuvant chemotherapy to see whether certain subtypes are more likely to respond to the treatment. (Source: Cancer Network)
Source: Cancer Network - June 7, 2013 Category: Cancer & Oncology Source Type: news

Stage and size using magnetic resonance imaging and endosonography in neoadjuvantly-treated rectal cancer.
CONCLUSION: MRI is preferable to use when assessing the size of large or stenotic rectal tumours. However, staging accuracy is improved by combining MRI with ERUS. PMID: 23745028 [PubMed - in process] (Source: World Journal of Gastroenterology)
Source: World Journal of Gastroenterology - June 7, 2013 Category: Gastroenterology Authors: Swartling T, Kälebo P, Derwinger K, Gustavsson B, Kurlberg G Tags: World J Gastroenterol Source Type: research

Phase II Trial of Neoadjuvant Docetaxel and CG1940/CG8711 Followed by Radical Prostatectomy in Patients With High-Risk Clinically Localized Prostate Cancer.
CONCLUSIONS: Neoadjuvant docetaxel/GVAX is safe and well tolerated in patients with high-risk locally advanced PC. No evidence of increased intraoperative hemorrhage or increased length of hospital stay postoperatively was noted. These results justify further study of neoadjuvant immunotherapy. PMID: 23740935 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - June 5, 2013 Category: Cancer & Oncology Authors: Vuky J, Corman JM, Porter C, Olgac S, Auerbach E, Dahl K Tags: Oncologist Source Type: research

Radiation Therapy and Esophageal CancerRadiation Therapy and Esophageal Cancer
Neoadjuvant chemoradiotherapy followed by surgical resection is the current standard of care for localized cancer of the esophagus. What's on the horizon? Cancer Control: Journal of the Moffitt Cancer Center (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - June 3, 2013 Category: Radiology Tags: Hematology-Oncology Journal Article Source Type: news

Status of Sentinel Lymph Node for Breast Cancer
This article highlights the overall survival and disease-free survival data as reported from the clinical trials. This article also reviews the status of SLN procedures and the following: male breast cancer, the roles of various imaging modalities (single-photon emission computed tomography/computed tomography, positron emission tomography/computed tomography, and ultrasound), ductal carcinoma in situ, extra-axillary SLNs, SLNB after neoadjuvant chemotherapy, radiation exposure to patients and medical personnel, and a new radiotracer that is the first to label SLNs not by particle trapping but by specific macrophage recept...
Source: Seminars in Nuclear Medicine - June 3, 2013 Category: Radiology Authors: Valeria M. Moncayo, John N. Aarsvold, Sandra F. Grant, Scott C. Bartley, Naomi P. Alazraki Source Type: research

Radionuclide Response Assessment of Breast Cancer
Preoperative systemic therapy with cytotoxic or biologic anticancer regimens has gained significant popularity in the management of breast cancer. Moreover, there is a worldwide paradigm shift toward an individualized approach to identify predictive surrogate markers for stratifying patients into distinct subgroups to improve outcome after neoadjuvant or adjuvant therapy. Although achievement of pathologic complete response constitutes the gold standard for assessing therapeutic efficacy only a minority of patients achieve a pathologic complete response. Imaging has evolved to play a crucial role in monitoring treatment ef...
Source: Seminars in Nuclear Medicine - June 3, 2013 Category: Radiology Authors: Lale Kostakoglu Source Type: research

[Comment] Sentinel node biopsy and neoadjuvant chemotherapy
Use of sentinel-lymph-node biopsy as standard care for axillary staging in patients with clinically node-negative (cN0) breast cancer is supported by scientific literature covering all aspects of the procedure. Women with negative sentinel lymph nodes do not need axillary dissection because axillary local recurrence after the biopsy procedure is rare (<1%). Furthermore, axillary-lymph-node dissection offers no benefit over sentinel-lymph-node biopsy with respect to survival or morbidity. (Source: The Lancet Oncology)
Source: The Lancet Oncology - June 1, 2013 Category: Cancer & Oncology Authors: Hiram S Cody Tags: Comment Source Type: research

[Articles] Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study
Sentinel-lymph-node biopsy is a reliable diagnostic method before neoadjuvant chemotherapy. After systemic treatment or early sentinel-lymph-node biopsy, the procedure has a lower detection rate and a higher false-negative rate compared with sentinel-lymph-node biopsy done before neoadjuvant chemotherapy. These limitations should be considered if biopsy is planned after neoadjuvant chemotherapy. (Source: The Lancet Oncology)
Source: The Lancet Oncology - June 1, 2013 Category: Cancer & Oncology Authors: Thorsten Kuehn, Ingo Bauerfeind, Tanja Fehm, Barbara Fleige, Maik Hausschild, Gisela Helms, Annette Lebeau, Cornelia Liedtke, Gunter von Minckwitz, Valentina Nekljudova, Sabine Schmatloch, Peter Schrenk, Annette Staebler, Michael Untch Tags: Articles Source Type: research

Parameterizing the Logistic Model of Tumor Growth by DW-MRI and DCE-MRI Data to Predict Treatment Response and Changes in Breast Cancer Cellularity during Neoadjuvant Chemotherapy.
Abstract Diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging (MRI) data of 28 patients were obtained pretreatment, after one cycle, and after completion of all cycles of neoadjuvant chemotherapy (NAC). For each patient at each time point, the tumor cell number was estimated using the apparent diffusion coefficient and the extravascular extracellular (v e) and plasma volume (v p) fractions. The proliferation/death rate was obtained using the number of tumor cells from the first two time points in conjunction with the logistic model of tumor growth, which was then used to predict tumor cellula...
Source: Translational Oncology - June 1, 2013 Category: Cancer & Oncology Authors: Atuegwu NC, Arlinghaus LR, Li X, Chakravarthy AB, Abramson VG, Sanders ME, Yankeelov TE Tags: Transl Oncol Source Type: research

CDC25A Protein Stability Represents a Previously Unrecognized Target of HER2 Signaling in Human Breast Cancer: Implication for a Potential Clinical Relevance in Trastuzumab Treatment.
Abstract The CDC25A-CDK2 pathway has been proposed as critical for the oncogenic action of human epidermal growth factor receptor 2 (HER2) in mammary epithelial cells. In particular, transgenic expression of CDC25A cooperates with HER2 in promoting mammary tumors, whereas CDC25A hemizygous loss attenuates the HER2-induced tumorigenesis penetrance. On the basis of this evidence of a synergism between HER2 and the cell cycle regulator CDC25A in a mouse model of mammary tumorigenesis, we investigated the role of CDC25A in human HER2-positive breast cancer and its possible implications in therapeutic response. HER2 sta...
Source: Neoplasia - June 1, 2013 Category: Cancer & Oncology Authors: Brunetto E, Ferrara AM, Rampoldi F, Talarico A, Cin ED, Grassini G, Spagnuolo L, Sassi I, Ferro A, Cuorvo LV, Barbareschi M, Piccinin S, Maestro R, Pecciarini L, Doglioni C, Cangi MG Tags: Neoplasia Source Type: research

[Radiation therapy in thyroid cancer].
Abstract Anaplastic thyroid cancers represent 1-2% of all thyroid tumours and are of very poor prognosis even with multimodality treatment including external beam radiation therapy. Conversely, differentiated thyroid carcinomas (at least 80% of thyroid cancers) hamper good prognosis with surgery with or without radioiodine and there is hardly any room for external beam radiation therapy. Insular and medullar carcinomas have intermediary prognosis and are rarely irradiated. We aimed to update recommendations for external beam irradiation in these different clinical situations and put in light the benefits of new irr...
Source: Cancer Radiotherapie - June 1, 2013 Category: Cancer & Oncology Authors: Sun XS, Guevara N, Fakhry N, Sun SR, Marcy PY, Santini J, Bosset JF, Thariat J Tags: Cancer Radiother Source Type: research

Pathologic and oncologic outcomes in locally advanced gastric cancer with neoadjuvant chemotherapy or chemoradiotherapy.
Conclusion: CCRTx rather than CTx appears to be more effective for achieving good pathologic response. Although favorable pathologic response has been achieved after neoadjuvant treatment, the survival benefit remains controversial. PMID: 23709422 [PubMed - in process] (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - May 31, 2013 Category: Universities & Medical Training Authors: An JY, Kim HI, Cheong JH, Hyung WJ, Kim CB, Noh SH Tags: Yonsei Med J Source Type: research

Changes in Indications and Oncological Outcomes of Radical Prostatectomy After 2000--Data From 1268 Japanese Patients Treated with Radical Prostatectomy Between 2000 and 2009.
CONCLUSIONS: Age at radical prostatectomy for men with localized prostate cancer was higher in Japan than in the USA or Europe. Prostate-specific antigen, non-organ-confined disease and tumor volume decreased during the study period, whereas Gleason score 7 and intermediate-risk disease increased during the study period. This information enables comparison of outcomes between various treatments, between various geographic regions and between various time periods. PMID: 23729494 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - May 31, 2013 Category: Cancer & Oncology Authors: Mitsuzuka K, Koie T, Narita S, Kaiho Y, Yoneyama T, Tsuchiya N, Kakoi N, Kawamura S, Tochigi T, Ohyama C, Habuchi T, Yamaguchi T, Arai Y Tags: Jpn J Clin Oncol Source Type: research

ASCO: Neoadjuvant Therapy Options and Clinical Trials in Breast Cancer
Ahead of the ASCO 2013 meeting we discuss neoadjuvant therapy options and clinical trials in breast cancer, as well as the opportunities for targeted therapies in post-neoadjuvant trials. (Source: Cancer Network)
Source: Cancer Network - May 29, 2013 Category: Cancer & Oncology Source Type: news

Vemurafenib As Neoadjuvant Treatment for Unresectable Regional Metastatic Melanoma [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 29, 2013 Category: Cancer & Oncology Authors: Koers, Francken, Haanen, Woerdeman, van der Hage Tags: Surgery, Combined Modality, Translational Oncology DIAGNOSIS IN ONCOLOGY Source Type: research

A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma
Conclusions: Our study indicates that neoadjuvant chemoradiation followed by one cycle of capecitabine before surgery has a good treatment efficacy, with only mild toxicities associated with chemoradiation and acceptable surgical complications. Treatment response was an early surrogate marker and correlated to oncologic prognosis. (Source: Radiation Oncology)
Source: Radiation Oncology - May 29, 2013 Category: Cancer & Oncology Authors: Ji ZhuWeilie GuPeng LianWeiqi ShengGang CaiDebing ShiSanjun CaiZhen Zhang Source Type: research

Population-based validation of a policy change to use long-term androgen deprivation therapy for cT3-4 prostate cancer: Impact of the EORTC22863 and RTOG 85-31 and 92-02 trials.
CONCLUSIONS: This population-based study demonstrated improved overall survival following a policy change to use of prolonged ADT with curative RT for patients with T3-T4 prostate cancer. PMID: 23726114 [PubMed - as supplied by publisher] (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - May 29, 2013 Category: Radiology Authors: Tran E, Paquette M, Pickles T, Jay J, Hamm J, Liu M, Lim J, Keyes M, Kwan W, Tyldesley S Tags: Radiother Oncol Source Type: research

A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer
CONCLUSIONSPreoperative therapy with full‐dose gemcitabine, oxaliplatin, and RT was feasible and resulted in a high percentage of R0 resections. The current results are particularly encouraging, because the majority of patients had borderline resectable disease. Cancer 2013. © 2013 American Cancer Society. (Source: Cancer)
Source: Cancer - May 29, 2013 Category: Cancer & Oncology Authors: Edward J. Kim, Edgar Ben‐Josef, Joseph M. Herman, Tanios Bekaii‐Saab, Laura A. Dawson, Kent A. Griffith, Isaac R. Francis, Joel K. Greenson, Diane M. Simeone, Theodore S. Lawrence, Daniel Laheru, Christopher L. Wolfgang, Terence Williams, Mark Bloomst Tags: Original Article Source Type: research

Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer
M-E Taplin & W K Oh (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - May 28, 2013 Category: Urology & Nephrology Authors: M D GalskyW XieM NakabayashiR W RossF M FennessyC M TempanyT K ChoueiriK KhineP W KantoffM-E TaplinW K Oh Tags: neoadjuvant chemotherapy endorectal MRI intermediate end points Source Type: research

Neoadjuvant-intensified treatment for rectal cancer: Time to change?
CONCLUSION: The results of this study suggest oxaliplatin chemotherapy has a beneficial effect on overall survival, likely due to an increase in local tumor control. PMID: 23716984 [PubMed - in process] (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - May 28, 2013 Category: Gastroenterology Authors: Musio D, De Felice F, Bulzonetti N, Guarnaccia R, Caiazzo R, Bangrazi C, Raffetto N, Tombolini V Tags: World J Gastroenterol Source Type: research

Detection of Truncated HER2 Forms in Formalin-Fixed, Paraffin-Embedded Breast Cancer Tissue Captures Heterogeneity and Is Not Affected by HER2-Targeted Therapy.
Abstract Truncated forms of HER2, previously identified in subsets of HER2-positive breast cancer, originate from proteolytic extracellular domain (ECD) cleavage or alternative translation initiation. They lack ECD but may retain intracellular domain functionality, potentially associated with unfavorable prognosis, metastasis, and decreased sensitivity to antibody-based HER2-targeted therapy. To study the distribution of truncated HER2 in breast cancer, we detected loss of membrane-bound ECD independently of its molecular origin in paraffin sections, combining multispectral unmixing of chromogenic duplex IHC for HE...
Source: Am J Pathol - May 28, 2013 Category: Pathology Authors: Krüger JM, Thomas M, Korn R, Dietmann G, Rutz C, Brockhoff G, Specht K, Hasmann M, Feuerhake F Tags: Am J Pathol Source Type: research

Prognostic impact of preoperative hematological disorders and a risk stratification model in bladder cancer patients treated with radical cystectomy
ConclusionsThis is the first report to show the significance of combining preoperative hemoglobin with the pathology of radical cystectomy specimens as an independent predictor for disease‐specific survival, and it also represents the largest contemporary series to date demonstrating that two types of preoperative hematological disorders, assessed by hemoglobin and C‐reactive protein, are independent predictors in bladder cancer patients treated with radical cystectomy. Our risk stratification model could provide physicians with useful prognostic information for identifying patients who might be candidates for multimod...
Source: International Journal of Urology - May 27, 2013 Category: Urology & Nephrology Authors: Takehiro Sejima, Shuichi Morizane, Akihisa Yao, Tadahiro Isoyama, Motoaki Saito, Takashi Amisaki, Tsutomu Koumi, Atsushi Takenaka Tags: Original Article Source Type: research

Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer (Br J Surg 2013; 100: 933-939).
PMID: 23640670 [PubMed - in process] (Source: The British Journal of Surgery)
Source: The British Journal of Surgery - May 26, 2013 Category: Surgery Authors: Harris DA Tags: Br J Surg Source Type: research

Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer.
CONCLUSION: Delaying surgery until the 15th or 16th week after the start of CRT (10-11 weeks from the end of CRT) seemed to result in the highest chance of a pCR. PMID: 23536485 [PubMed - in process] (Source: The British Journal of Surgery)
Source: The British Journal of Surgery - May 26, 2013 Category: Surgery Authors: Sloothaak DA, Geijsen DE, van Leersum NJ, Punt CJ, Buskens CJ, Bemelman WA, Tanis PJ, Dutch Surgical Colorectal Audit Tags: Br J Surg Source Type: research

How to define and manage borderline resectable pancreatic cancer.
This article reviews current definitions, treatment sequences, outcomes, and prognostic factors associated with BLR pancreatic cancer. Further clarification and consensus on the definition of BLR pancreatic cancer will allow for further data collection and cooperation in future efforts to make progress and standardize treatment. PMID: 23632151 [PubMed - in process] (Source: The Surgical Clinics of North America)
Source: The Surgical Clinics of North America - May 26, 2013 Category: Surgery Authors: Papavasiliou P, Chun YS, Hoffman JP Tags: Surg Clin North Am Source Type: research

Could testosterone have a therapeutic role in prostate cancer?
CONCLUSION: Investigation of the molecular pathways of apoptosis through activation of the membrane androgen receptors in the androgen-independent PCa cell is important on the one hand because future manipulation of this mechanism can help with understanding and interpreting unknown to date characteristics of PCa and on the other hand, can contribute to the establishment of activators of membrane androgen receptors. In addition, study of the testosterone-albumin complex can constitute the basis for future treatments for PCa. PMID: 23504676 [PubMed - in process] (Source: Urology Journal)
Source: Urology Journal - May 26, 2013 Category: Urology & Nephrology Authors: Stamatiou K, Pierris N Tags: Urol J Source Type: research

Retrospective Analysis of Clinicopathological Characteristics and Family History Data of Early-Onset Breast Cancer: A Single-Institutional Study of Hungarian Patients.
Abstract Patients at young age (≤35 years) diagnosed with breast cancer (BC) are considered to have poor prognosis. The aim of the present study was to retrospectively analyse clinicopathological characteristics and prognosis in a group of young BC patients. We included women diagnosed with invasive breast carcinoma younger than/or at the age of 35 years. Between 1999 and 2009, 107 women with early-onset BC were selected from the database of the 2nd Department of Pathology at Semmelweis University. For clinicopathological comparison, 55 women (36-45 years), 214 women (46-65 years), 110 women (66-75 years) an...
Source: Pathology Oncology Research - May 26, 2013 Category: Pathology Authors: Madaras L, Baranyák Z, Kulka J, Szász AM, Kovács A, Lan PH, Székely B, Dank M, Nagy T, Kiss O, Harsányi L, Barbai T, Kenessey I, Tőkés AM Tags: Pathol Oncol Res Source Type: research

Multifocal anaplastic pancreatic carcinoma requiring neoadjuvant chemotherapy and total pancreatectomy: report of a case.
We describe a case of multifocal anaplastic pancreatic carcinoma treated with neoadjuvant FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil and leucovorin) and total pancreatectomy with subsequent patient disease-free survival currently at 12 months. DISCUSSION: The goal for anaplastic pancreatic carcinoma treatment should continue to be complete surgical resection. Optimum chemotherapeutic options continue to be investigated. PMID: 23669483 [PubMed - in process] (Source: JOP)
Source: JOP - May 25, 2013 Category: Gastroenterology Authors: Jones TS, Jones EL, McManus M, Shah R, Gajdos C Tags: JOP Source Type: research

Variation in Colorectal Cancer Treatment and Survival: A Cohort Study Covering the East Anglia Region
ConclusionsDetailed analysis of demographic, disease and treatment factors are required when comparing the survival of individuals with colorectal cancer across hospitals. Results imply that cancer management was not consistent across East Anglia in 1999‐2005 but the reasons for this are uncertain. Nevertheless, five‐year age‐standardised survival with colon cancer in the Anglia Cancer Network region is currently amongst the best in the UK.This article is protected by copyright. All rights reserved. (Source: Colorectal Disease)
Source: Colorectal Disease - May 25, 2013 Category: Gastroenterology Authors: Jane Warwick, Olivia Will, Prue Allgood, Richard Miller, Stephen Duffy, David Greenberg Tags: Original Article Source Type: research

The association between pre‐treatment haemoglobin levels, morphometric characteristics of the tumour, response to neoadjuvant treatment and long‐term outcomes in patients with locally advanced rectal cancers
ConclusionPre‐treatment level of Hb might be used as a biomarker of rectal tumour morphology, response to neoadjuvant chemoradiation and risk of local recurrence.This article is protected by copyright. All rights reserved. (Source: Colorectal Disease)
Source: Colorectal Disease - May 25, 2013 Category: Gastroenterology Authors: A. A. Khan, M. Klonizakis, A. Shabaan, R. Glynne‐Jones Tags: Original Article Source Type: research

Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in Monitoring the Response of Breast Cancer to Neoadjuvant Chemotherapy: A Meta-Analysis.
CONCLUSIONS: Analysis of the findings suggests that FDG-PET has moderately high sensitivity and specificity in early detection of responders from nonresponders, and can be applied in the evaluation of breast cancer response to neoadjuvant chemotherapy in patients with breast cancer. PMID: 23714689 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 25, 2013 Category: Cancer & Oncology Authors: Mghanga FP, Lan X, Bakari KH, Li C, Zhang Y Tags: Clin Breast Cancer Source Type: research

Current concepts in the diagnosis and management of poorly differentiated gastrointestinal neuroendocrine carcinomas.
Abstract Poorly differentiated neuroendocrine carcinomas (PDNEC) are rare tumours that can originate from any site of the gastrointestinal tract exhibiting an overall aggressive behaviour that may vary between tumours according to the degree of cellular proliferation. The majority of PDNEC are locally advanced or metastatic at presentation, and are only infrequently associated with secretory hormonal syndromes. PDNEC exhibit aggressive histological features (high mitotic rate, high Ki67 labelling index and presence of necrosis) and are further subdivided into two morphological subgroups, small and large cell varian...
Source: Endokrynologia Polska - May 24, 2013 Category: Endocrinology Authors: Koumarianou A, Chatzellis E, Boutzios G, Tsavaris N, Kaltsas G Tags: Endokrynol Pol Source Type: research

Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy.
CONCLUSION: This is the first reported LAPC case in which neoadjuvant chemotherapy alone has been shown to lead to demonstrated pCR. CA19-9 levels, but not imaging criteria, were useful for response prediction and timing of the Whipple's procedure. The findings in this case suggest possible conceptual changes in the treatment approach for LAPC, and indicate that the new effective chemotherapy regimens should be integrated into clinical trials for LAPC. PMID: 23486001 [PubMed - in process] (Source: Onkologie)
Source: Onkologie - May 24, 2013 Category: Cancer & Oncology Authors: Hartlapp I, Müller J, Kenn W, Steger U, Isbert C, Scheurlen M, Germer CT, Einsele H, Kunzmann V Tags: Onkologie Source Type: research

Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: A randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy.
CONCLUSION: The results of this study demonstrate that responses were equal to 4 or 6 months of exemestane treatment. Therefore, we propose that the rates of breast-conserving surgery could be maximized by 4 months of treatment. Furthermore, in addition to using exemestane as a preoperative treatment in post-menopausal women with ER-positive breast cancer, we envision administering the drug over the long term under careful clinical supervision. PMID: 23587451 [PubMed - in process] (Source: Breast)
Source: Breast - May 24, 2013 Category: Cancer & Oncology Authors: Hojo T, Kinoshita T, Imoto S, Shimizu C, Isaka H, Ito H, Imi K, Wada N, Ando M, Fujiwara Y Tags: Breast Source Type: research

Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection
Conclusions: The DOX-I2 combination exerts antineoplastic, chemosensitivity, and cardioprotective effects and could be a promising strategy against breast cancer progression. (Source: Molecular Cancer)
Source: Molecular Cancer - May 24, 2013 Category: Cancer & Oncology Authors: Yunuen AlfaroGuadalupe DelgadoAlfonso CárabezBrenda AnguianoCarmen Aceves Source Type: research

Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy
In this study, we aimed to evaluate the prognostic significance of the neutrophil-lymphocyte ratio (NLR) in patients with stage III-IV gastric cancer who received neoadjuvant chemotherapy. Methods: We enrolled 46 patients in this study. The NLR was divided into two groups: high (>2.5) and low ( (Source: World Journal of Surgical Oncology)
Source: World Journal of Surgical Oncology - May 24, 2013 Category: Cancer & Oncology Authors: Hailong JinGeer ZhangXiaosun LiuXiaokun LiuChao ChenHang YuXiaomei HuangQing ZhangJiren Yu Source Type: research

Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin
Highlights: Abstract: Biomarkers predicting response to neoadjuvant chemotherapy in locally confined breast cancer (LBC) are highly needed. We prospectively assessed serial blood levels of apoptotic biomarkers nucleosomes, DNAse activity, cytokeratin-18 fragments (M30) and survivin in 51 LBC patients and correlated them with response to neoadjuvant treatment and established tumor markers. As controls, we used 31 healthy subjects, 13 patients with benign diseases and 28 with metastatic breast cancer (MBC). Levels of nucleosomes and survivin were elevated in LBC and MBC while M30, CEA and CA 15-3 levels were only elevated in...
Source: Cancer Letters - May 24, 2013 Category: Cancer & Oncology Authors: Oliver J. Stoetzer, Debora M.I. Fersching, Christoph Salat, Oliver Steinkohl, Christian J. Gabka, Ulrich Hamann, Michael Braun, Axel-Mario Feller, Volker Heinemann, Barbara Siegele, Dorothea Nagel, Stefan Holdenrieder Tags: Research Articles Source Type: research

Predicting Pathologic Complete Response to neoadjuvant chemotherapy in breast cancer using Sparse Logistic Regression.
Abstract We utilised Sparse Logistic Regression (SLR) to build two sparse and interpretable predictors. The first one (SLR-65) was based on a signature consisting of the top 65 probe sets (59 genes) differentially expressed between Pathologic Complete Response (PCR) and Residual Disease (RD) cases, and the second one (SLR-Notch) was based on the genes involved in the Notch singling related pathways (113 genes). The two predictors produced better predictions than the predictor in a previous study. The SLR-65 selected 16 informative genes and the SLR-Notch selected 12 informative genes. PMID: 23649738 [PubMed - i...
Source: International Journal of Bioinformatics Research and Applications - May 23, 2013 Category: Bioinformatics Authors: Hu W Tags: Int J Bioinform Res Appl Source Type: research

Lymph Node Extramedullary Hematopoiesis in Breast Cancer Patients Receiving Neoadjuvant Therapy: A Potential Diagnostic Pitfall
Extramedullary hematopoiesis (EMH) develops as a compensatory mechanism associated with hematologic processes but it may occur in association with chemotherapy. Three cases of EMH arising in axillary lymph nodes following neoadjuvant therapy for breast carcinoma are reported herein. Three women ranging in age from 41 to 47 years presented with unilateral breast masses measuring 0.6 to 4.0 cm in greatest dimension and were diagnosed with infiltrating ductal carcinoma, grade III by core needle biopsies. Two of the tumors were triple negative and one was estrogen receptor positive. All patients subsequently received neoadjuva...
Source: International Journal of Surgical Pathology - May 23, 2013 Category: Pathology Authors: Prieto-Granada, C., Setia, N., Otis, C. N. Tags: Pitfalls in Pathology Source Type: research

Gene methylation in rectal cancer: Predictive marker of response to chemoradiotherapy?
Abstract Although numerous studies have focused on the link between CpG island methylator phenotypes and the development of colorectal cancer, few studies have dealt specifically with methylation profiling in rectal cancer and its role in predicting response to neoadjuvant chemoradiotherapy (NCRT). We characterized methylation profiles in normal and neoplastic tissue samples from patients with rectal cancer and assessed the role of this molecular profile in predicting chemoradioactivity.We evaluated 74 pretreatment tumor samples and 16 apparently normal tissue biopsies from rectal cancer patients submitted to NCRT. The met...
Source: Journal of Cellular Physiology - May 23, 2013 Category: Cytology Authors: Chiara Molinari, Valentina Casadio, Flavia Foca, Chiara Zingaretti, Massimo Giannini, Andrea Avanzolini, Enrico Lucci, Luca Saragoni, Alessandro Passardi, Dino Amadori, Daniele Calistri, Wainer Zoli Tags: Original Research Article Source Type: research

Pre‐treatment MR imaging of lymph nodes in rectal cancer, an opinion based review
This article is protected by copyright. All rights reserved. (Source: Colorectal Disease)
Source: Colorectal Disease - May 22, 2013 Category: Gastroenterology Authors: Regina G.H. Beets‐Tan Tags: Special Article Source Type: research

Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)
Conclusions Neoadjuvant bevacizumab, docetaxel and carboplatin resulted in an encouraging pCR rate and negligible wound healing problems after surgery. (Source: Annals of Oncology)
Source: Annals of Oncology - May 21, 2013 Category: Cancer & Oncology Authors: Kim, H. R., Jung, K. H., Im, S.- A., Im, Y.- H., Kang, S. Y., Park, K. H., Lee, S., Kim, S.- B., Lee, K.- H., Ahn, J. S., Kim, S. I., Sohn, J. H. Tags: breast cancer Source Type: research